WO1998033482A1 - Pain reducing parenteral liposome formulation - Google Patents
Pain reducing parenteral liposome formulation Download PDFInfo
- Publication number
- WO1998033482A1 WO1998033482A1 PCT/US1998/001430 US9801430W WO9833482A1 WO 1998033482 A1 WO1998033482 A1 WO 1998033482A1 US 9801430 W US9801430 W US 9801430W WO 9833482 A1 WO9833482 A1 WO 9833482A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- drug
- deoxy
- lipid
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to pain reducing parenteral formulation in liposome system. More particularly, it relates to a parenteral formulation comprising a macrolide drug entrapped in a liposome vesicle.
- the formulations of the invention are effective in substantially reducing the pain typically associated with the injection of macrolide antibiotics.
- Injection site pain following a parenteral administration is generally caused by pharmacological/physiological reactions between drug molecules and the local tissue. Pain reducing formulations in the form of either micelles or emulsions for intravenous adininistration of macrolide antibiotics have been disclosed by Lovell, et al.. International Journal of Pharmaceuticals, 109, 45-57, (1994); Cannon, et al., International Journal of Pharmaceutics, 114, 65-74, (1995); and Klement, et al., British Journal of Anesthesia, 67, 281-284, (1991). For emulsion systems, the drugs are entrapped in small oil droplets.
- Emulsions are generally stabilized by some surfactants which create an interfacial layer to separate oil phase and the aqueous phase.
- This interfacial layer is a barrier to reduce direct contact of the drug molecules to the local tissue around the injection site.
- this barrier is very dynamic. Drug molecules travel in and out of the interface very frequently. This property limits the effectiveness of emulsion on injection pain reduction.
- drugs are entrapped in micelles consisting of surfactants.
- Polar head groups of the surfactant molecules face the aqueous bulk solution and the lipophilic tails face toward the core to form spherical or cylindrical structures.
- the packing of the head groups is generally not tight and is very dynamic allowing rapid release of the drug following an injection. Similarly, the effectiveness of the micelles in reducing injection site pain is limited.
- Figure 1 compares the response to pain by successive infusion of saline solution, clarithromvcin solution and saline solution using Rat Tail Vein Infusion Pain Model.
- Figure 2 compares the response to pain by successive infusion of saline, placebo liposome, saline, clarithromycin liposome formulation of the invention containing phosphatidylglycerol, saline and clarithromycin solution using Rat Tail Vein Infusion Pain Model.
- Figure 3 compares the response to pain by successive infusion of saline, placebo liposome, saline, clarithromycin liposome formulation of the invention containing dimyristoyl phosphatidic acid, saline, clarithromycin solution and saline using Rat Tail Vein Infusion Pain Model.
- Figure 4 compares the response to pain by successive infusion of saline, placebo liposome, saline, ABT-229 liposome formulation of Example 3 of the invention, saline, placebo rV (lactobionic acid solution), saline, ABT-229 solution IV, and saline using Rat Tail Vein Infusion Pain Model.
- Figure 5 compares the response to pain by successive infusion of saline, placebo liposome, saline, ABT-773 liposome formulation of Example 4 of the invention, saline, placebo V (lactobionic acid solution), saline, ABT-773 solution V, and saline using Rat Tail Vein Infusion Pain Model.
- the present invention is directed towards a pain-reducing parenteral formulation comprising a macrolide drug entrapped in a liposome vesicle comprising a lipid.
- the formulations of the invention are effective on injection site pain reduction caused by macrolide drug molecules.
- the present invention is directed to a method of reducing injection pain site caused by a macrolide drug comprising administering a parenteral formulation comprising a macrolide drug entrapped in a liposome vesicle.
- liposome vesicle refers to a single bilayer or multiple bilayers vesicles consisting of phospholipids or other lipids in which an aqueous volume is entirely enclosed by a membrane composed of lipid molecules.
- the parenteral formulations of the invention comprise a macrolide drug entrapped in liposome vesicles which comprise a lipid.
- the macrolide drugs can be selected from derivatives of erythromycins A, B, C, and D; clarithromycin; azithromycin; dirithromycin; josamycin; midecamycin; kitasamycin; roxithromycin; rokitamycin; oleandomycin; miocamycin; flurithromycin; rosaramicin; 8,9-anhydro-4"-deoxy-3'-N-desmethyl-3'-N-ethylerythromycin B,
- ABT-269 6,9-hemiacetal
- ABT-773 1,12-cyclic carbamate
- the macrolide drug used in the formulation is clarithromycin, ABT-229, and ABT-773. More preferably, the macrolide drug used in the formulation is clarithromycin.
- the liposome vesicle is formed when lipids are dispersed in an aqueous medium.
- lipids that can be used in forming the liposomes are naturally occurring lipids, synthetic lipids and semi-synthetic lipids.
- the naturally occurring lipids include phospholipids, phosphatidyl choline, fatty acids, double chain secondary amines and cholesterol derivatives, and the like.
- Synthetically obtained lipids include, but are not limited to, ether-linked phosphatidyl choline, dimyristyl lecithin, dipalmitoyl lecithin, distearoyl lecithin.
- the lipids are phospholipids which include phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl-inositol, phosphatidyl serine, sphingomyelin, ether- linked phosphatidyl choline, dimyristoyl phosphatidyl choline, dimyristoyl phosphatidic acid, dimyristoyl phosphatidyl glycerol, phosphatidic acid and the like.
- the molar ratio of the drug molecules to the lipid can be as low as 1:2 or may contain a higher proportion of lipid such as 1 : 100. Preferably, this molar ratio varies from 1:8 to 1:20.
- the molar ratio depends upon the drug being used but will assure the presence of a sufficient number of neutral and/or negatively charged lipids and the drug to form a stable complex with most drugs.
- the liposome vesicles comprise both the neutral and negatively charged lipids.
- Illustrative of neutral lipids include phosphatidyl serine and phosphatidyl ethanolamine.
- the molar ratio of a negatively charged phospholipid to the drug varies from about 0.5 to about 3.0 with a ratio of drug to a neutral phospholipid being from about 1.0 to about 7.0.
- the pH of the formulation can range from pH 3 to pH 11.
- the pH of the formulation is adjusted by adding an alkali or an acid as needed.
- the requisite pH of the formulation is determined by the kind of drug to be entrapped and its solubility in water at ambient temperatures.
- the liposome formulation may contain other optional ingredients, which include minor amounts of nontoxic, auxiliary substances; such as antioxidants, e.g., butylated hydroxytoluene, alpha-tocopherol and ascorbyl palmitate, ascorbic acid, butylated hydroxyanisole, fumaric acid, malic acid, propyl gallate, sodium ascorbate. and sodium metabisulfite; and pH buffering agents; such as phosphates, glycine and the like. When naturally occurring phospholipids are used, it is recommended that the liposome formulation contain antioxidant to prevent the oxidation of the unsaturated bonds present in the fatty acid chains in the phospholipid.
- antioxidants e.g., butylated hydroxytoluene, alpha-tocopherol and ascorbyl palmitate, ascorbic acid, butylated hydroxyanisole, fumaric acid, malic acid, propyl gallate, sodium ascorbate. and sodium metabisulfite
- the liposome formulation may contain cryoprotective agent known to be useful in the art of preparing freeze-dried formulations, such as di- or polysaccharides or other bulking agent such as lysine. Further, isotonic agents typically added to maintain isomolarity with body fluids may be used. In a preferred embodiment, a di-saccharide or polysaccharide is used and functions both as a cryoprotective agent and as an isotonic agent.
- cryoprotective agent known to be useful in the art of preparing freeze-dried formulations, such as di- or polysaccharides or other bulking agent such as lysine.
- isotonic agents typically added to maintain isomolarity with body fluids may be used.
- a di-saccharide or polysaccharide is used and functions both as a cryoprotective agent and as an isotonic agent.
- a disaccharide or polysaccharide provides instantaneous hydration and the largest surface area for depositing a thin film of the drug-lipid complex.
- This thin film provides for faster hydration so that, when liposome is initially formed by adding the aqueous phase, the liposomes formed are of a smaller and more uniform particle size. This provides significant advantages in terms of manufacturing ease.
- the preferred liposomal composition of the present invention comprises a disaccharide or polysaccharide, in addition to the phospholipids.
- the disaccharide or polysaccharide is preferably chosen from among the group consisting of lactose, trehalose, maltose, maltotriose, palatinose, lactulose or sucrose, with lactose or trehalose being preferred.
- the liposomes comprise lactose or trehalose.
- the di- or polysaccharide is formulated in a preferred ratio of about 10-20 saccharide to 0.5-6.0 phospholipid mixture, respectively, even more preferably at a ratio from about 10 to 1.5-4.0.
- liposomes having extremely small and narrow particle size ranges not only tends to yield liposomes having extremely small and narrow particle size ranges, but also provides a liposome composition in which drug, in particular, may be incorporated in an efficient manner, i.e., with an encapsulation efficiency approaching 80-100%.
- liposomes made with a saccharide typically exhibit improved physical and chemical stability, such that they can retain an incorporated compound without leakage upon prolonged storage, either as a reconstituted liposomal suspension or as a cryodesiccated powder.
- the liposomes can be prepared by any of the methods known in the art. (See for example, R. R. C. New, "Liposomes, a Practical Approach", pp 1-161, IRL Press, ( 1990)). In one of the methods for preparation of liposomes, a solution of a macrolide drug, excipients and lipid in an organic solvent is formed and introduced into a round bottom flask.
- Suitable solvents include any volatile organic solvent, such as diethyl ether, acetone, methylene chloride, chloroform, piperidine, piperidine-water mixtures, methanol, tert-butanol, dimethyl sulfoxide, N-methyl-2-pyrrolidone, and mixtures thereof.
- the organic solvent is water-immiscible, such as methylene chloride, but water immiscibility is not required.
- the solvent chosen should not only be able to dissolve all of the components of the lipid film, but should also not react with, or otherwise deleteriously affect, these components to any significant degree.
- the organic solvent is then removed from the resulting solution to form a dry lipid film by any known laboratory technique that is not deleterious to the dry lipid film.
- the solvent is removed under a vacuum until all the organic solvent is evaporated.
- a rotary evaporator is immersed into a thermostated water bath at 40 C, evacuated, and rotated at 60 rpm. The evacuation and rotation is continued until all the solvent has evaporated from the solution and a dry lipid film has deposited on the walls of the flask.
- the residual solvent is removed by a vacuum pump for a minimum period of twenty four hours.
- the dry lipid film is then dispersed in an aqueous solution, preferably containing a disaccharide or polysaccharide, or a saline solution.
- aqueous solutions used during hydration of the film include sterile water, a calcium- and magnesium-free, phosphate-buffered (pH 7.2-7.4) sodium chloride solution, a 5% dextrose solution, or any other physiologically acceptable aqueous solution of one or more electrolytes.
- the aqueous solution is sterile.
- the volume of the aqueous solution used during hydration can vary greatly, but should be higher than about 35% and less than about 95% of the total volume.
- the flask is rotated at 60 rpm at room temperature until all the lipid film has been removed from the wall of the flask.
- the lipid dispersion is then allowed to stand for additional two hours at room temperature in order to complete the swelling process.
- the coarse liposome thus formed incorporates a drug-lipid complex.
- the hydration step should take place at a temperature that does not exceed about 40 C, preferably, at room temperature or lower.
- the particle size of the coarse liposome obtained is homogenized by passing the dispersion through a high-speed agitation devices; such as "Microfluidizer", for example, a MicrofluidicsTM Model 110F; a sonicator; a high-shear mixer; a homogenizer; or a standard laboratory shaker.
- a high pressure device such as a MicrofluidizerTM is used for agitation. In microfluidization, a great amount of heat is generated during the short period of time during which the fluid passes through a high pressure interaction chamber.
- the homogenization temperature is cooled down to a temperature no greater than 40 C after the composition passes through the zone of maximum agitation, e.g., the interaction chamber of a MicrofluidizerTM device.
- the homogenization temperature should preferably be room temperature or lower. While the pressure used in such high pressure devices is not critical, pressures from about 10,000 to about 16,000 psi are not uncommon. It is crucial that one obtains vesicles which are of right size and structure, and entrap materials with high efficiency and in such a way that materials do not leak out of the liposome once formed.
- the pH of the formulation is adjusted to a desired level by adding an alkali or an acid as the case may be.
- the liposome dispersion so obtained is aseptically filtered through a 0.2 ⁇ m filter using a syringe pump and the post filtrate weighed to determine filterability.
- the filtration potency of the prefiltrate and postfiltrate can be determined using High Performance Liquid Chromatography (HPLC).
- HPLC High Performance Liquid Chromatography
- the particle size distribution of the vesicles can be determined using a NICOMP (Model 370) submicron particle analyzer or other conventional particle size measuring techniques.
- the liposomal compositions of the invention provide liposomes of a sufficiently small particle size such that the aseptic filtration of the composition through a 0.2 ⁇ m hydrophilic filter can be accomplished efficiently.
- the particle size of the liposome can vary from about 10 nm to about 25 ⁇ m. A particularly preferred size range is below about 300 nm, more preferably below from about 250 nm. Most preferably, the particle size is below about 220 nm.
- Filterability can be tested by passing a liposome composition through a MicrofluidizerTM five times and withdrawing a sample with a syringe.
- the syringe is connected to a 0.2 ⁇ m hydrophilic filter and then placed in a syringe pump.
- the constant rate of piston movement is set at 10 ml/min, and filtrate is collected until the filter becomes blocked by large aggregates of liposome.
- the volume or weight of the filtrate is then measured and recorded in terms of ml/cm 2 or g/cm 2 , with a square centimeter being the effective filtration area.
- filterability for the purpose of the invention is defined as the maximum volume or weight of liposomal composition that can be filtered through 0.2 ⁇ m filter.
- the liposome compositions of the invention are typically administered parenterally.
- Injection may be intravenous, subcutaneous, intramuscular, intrathecal, intraperitoneal, and any other parenteral administrations.
- the quantity of the liposome formulation to be administered depends on the choice of active drug, the condition to be treated, the mode of administration, the individual subject and the judgment of the practitioner. Generally speaking, however, dose of active drug in the range of 0.05-50 mg/kg may be needed. The foregoing range is, of course, merely suggestive, as the number of variables in regard to an individual treatment regime is large. Therefore, considerable excursions from these recommended values are expected.
- the packing of bilayers in liposome vesicle is very tight with higher glass transition temperature than that of micelles and emulsion, and, therefore, the liposome vesicle is more rigid and less dynamic than micelles and emulsions.
- the physical barriers created by liposome of the invention, especially multibilayered liposome vesicles, are effective against rapid movement of the drug therefrom at the injection site after such infusion, thereby reducing the concomitant pain.
- Rat Tail Vein Infusion motor response model This model is based on the assumption that the movement of a rat during intravenous infusion will be proportional to the pain caused by the infusion.
- the rat male Spargue Dawley, 325 to 375 g
- Multiple test substances are infused successively in a desired sequence, through a butterfly needle inserted in the lateral tail vein of a rat. Movement of the cage is monitored by an accelerometer mounted at the base of the cage.
- the accelerometer signal is transmitted to a computer for data display and storage.
- Example 1(a) through 1(f) The formulations of Example 1(a) through 1(f), containing various ingredients in the amounts set forth below in Table 1 , were prepared by the following general method.
- a drug-lipid organic solution was prepared by dissolving PG, DMPC, clarithromycin, 5 and BHT in 25 ml of methylene chloride.
- the lipid solution is introduced in a round-bottomed flask.
- the flask is attached to a rotary evaporator, and immersed into in a thermostated water bath at 4 °C.
- the flask is rotated at 60 rpm and vacuum applied until all the solvent has evaporated from the solution and a dry lipid film has deposited on the walls of the flask.
- the trace residual solvent is removed by applying vacuum for a minimum period of 24
- the flask is then flushed with nitrogen and lactose solution added.
- the flask is rotated (60 rpm) at room temperature until all the lipid film has been removed from the wall of the flask.
- the lipid dispersion is allowed to stand for an additional 2 hours at room temperature in order to complete the swelling process.
- the particle size of the coarse liposome is reduced by passing the liposomal solution izs through a MicrofluidizerTM five times.
- the pH is adjusted to an appropriate value by adding an alkali or an acid.
- the liposomal dispersion is filtered through a 0.2 ⁇ m hydrophilic filter using a syringe pump and post filtrate weighed to determine filterability.
- the filtration potency of prefiltrate and postfiltrate is determined using an HPLC method.
- the particle size distribution is measured using a NICOMP submicron particle analyzer (Model 370). Table 2 below sets forth the various parameters for the formulations of Example 1(a) through 1 (f)
- the amount of clarithromycin contained in the formulation is 5 mg/ml of the dispersion.
- the particle size distribution of liposome is bimodal.
- a liposomal formulation was prepared in accordance with the method described in Example 1 Table 3 sets forth the amounts of the ingredients used to prepare the formulation
- the amount of clarithromycin in the formulation is 3 5 mg/ml of the dispersion
- the concentration (3.5 mg ml) was determined using an HPLC method.
- the pH of the suspension is 8.0 with the filtration potency of 100% and filterability of 0.31g/cm 2 .
- the particle size distribution of liposome is bimodal having particle size of 83.4/19.9 nm.
- Example 3 A liposomal formulation comprising ABT-229 was prepared in accordance with the method described in Example 1. Table 4 sets forth the amounts of the ingredients used to prepare the formulation.
- the amount of ABT-229 in the formulation is 2.5 mg/ml of the dispersion.
- the concentration (2.5 mg/ml) was determined using an HPLC method.
- the pH of the suspension is 8.0 with the filtration potency of 97.9% and filterability of >4.0 g/cm 2 .
- the particle size distribution of liposome is trimodal having particle size of 7.9/62.5/296.4 nm.
- a liposomal formulation comprising ABT-773 was prepared in accordance with the method described in Example 1.
- Table 5 sets forth the amounts of the ingredients used to prepare the formulation.
- the amount of ABT-773 in the formulation is 5.0 mg/ml of the dispersion.
- the concentration (5.0 mg/ml) was determined using an HPLC method.
- the pH of the suspension is 9.0 with the filtration potency of 103.4% and filterability of >4.0 g/cm 2 .
- the particle size distribution of liposome is unimodal having particle size of 15.4 nm.
- Example 5 This example illustrates the evaluation of pain reducing properties of the liposomal formulations using Rat Tail Vein Infusion Pain Model.
- Rats are initially acclimated to the restraining cage for a period of thirty minutes, one to five days prior to infusion of the test formulation.
- the formulations of the above examples are then infused by inserting a 23 gauge butterfly needle in the lateral tail vein of the rats.
- the needle is connected by tubing to a syringe pump and formulations are infused at 0.1 ml/minute. Infusion of each formulation is proceeded and following by saline. Movement of the cage is monitored by an accelerometer mounted at the base of the cage.
- the accelerometer signal is transmitted to a computer for data display and storage.
- Figure 1 illustrates the results of infusing 5 mg/ml clarithromycin lactobionic acid solution preceded and followed by saline. At this concentration, clarithromycin solution leads to a definite pain response.
- Figure 2 illustrates the results of the pain producing property of the formulation of the invention of Example 1 as compared to placebo liposomes, saline, and clarithromycin solution (5 mg/ml).
- the results are obtained by sequentially infusing saline, placebo liposomes, saline.
- the results clearly indicate that the rat showed no response to the placebo liposomes or the clarithromycin loaded liposomes.
- the pain response to the clarithromycin solution is typical for 5 mg/ml and similar to the results shown in Figure 1.
- Figure 3 illustrates the results of an experiment designed to compare the pain producing property of the formulation of Example 2 and free clarithromycin at 3.5 mg/ml.
- the results are obtained by sequentially infusing saline, placebo liposomes, saline, clarithromycin liposomes of Example 2, saline, clarithromycin solution, and saline using same individual rat throughout the experiment, thereby eliminating uncertainty caused by inter animal variability.
- the results clearly indicate that the rat showed no response to the placebo liposomes or the clarithromycin loaded liposomes.
- the pain response to clarithromycin solution is typical for 3.5 mg/ml and similar to the results obtained in Figure 1.
- Figures 4 illustrates the results of the pain producing property of the formulation of the invention of Example 3.
- the results are obtained by sequentially infusing saline, placebo liposome, saline, ABT-229 liposome formulation of Example 3, saline, placebo IV (lactobionic acid solution), saline, ABT-229 solution IV, and saline using Rat Tail Vein Infusion Pain Model using same individual rat throughout the experiment, thereby eliminating uncertainty caused by inter animal variability.
- the results clearly indicate that the rat showed no response to the placebo liposomes, placebo IV or the ABT-229 loaded liposomes but showed the pain response to the ABT-229 solution IV.
- placebo IV was infused to demonstrate that the pain response is associated with ABT-229 and not the lactobionic acid itself.
- Figures 5 illustrates the results of the pain producing property of the formulation of the invention of Example 4.
- the results are obtained by sequentially infusing saline, placebo liposome, saline, ABT-773 liposome formulation of Example 4, saline, placebo V (lactobionic acid solution), saline, ABT-773 solution V, and saline using same individual rat throughout the experiment, thereby eliminating uncertainty caused by inter animal variability.
- the results clearly indicate that the rat showed no response to the placebo liposomes, placebo V or the ABT-773 loaded liposomes but showed the pain response to the ABT-773 solution.
- placebo V lactobionic acid solution
- Example placebo V was infused to demonstrate that the pain response is associated with ABT- 773 and not the lactobionic acid itself.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002279259A CA2279259A1 (en) | 1997-02-04 | 1998-01-26 | Pain reducing parenteral liposome formulation |
EP98903718A EP0975330A1 (en) | 1997-02-04 | 1998-01-26 | Pain reducing parenteral liposome formulation |
AU60414/98A AU6041498A (en) | 1997-02-04 | 1998-01-26 | Pain reducing parenteral liposome formulation |
JP53298498A JP2001511780A (en) | 1997-02-04 | 1998-01-26 | Analgesic parenteral liposome formulation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79406497A | 1997-02-04 | 1997-02-04 | |
US08/794,064 | 1997-02-04 | ||
US360698A | 1998-01-07 | 1998-01-07 | |
US09/003,606 | 1998-01-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998033482A1 true WO1998033482A1 (en) | 1998-08-06 |
Family
ID=26671961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/001430 WO1998033482A1 (en) | 1997-02-04 | 1998-01-26 | Pain reducing parenteral liposome formulation |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0975330A1 (en) |
JP (1) | JP2001511780A (en) |
AU (1) | AU6041498A (en) |
CA (1) | CA2279259A1 (en) |
WO (1) | WO1998033482A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000078772A2 (en) * | 1999-06-19 | 2000-12-28 | The Victoria University Of Manchester | Antibiotic agents |
US6605613B2 (en) | 1998-12-07 | 2003-08-12 | Novartis Ag | Macrolides |
JP2003523938A (en) * | 1999-04-16 | 2003-08-12 | コーサン バイオサイエンシーズ, インコーポレイテッド | Macrolide anti-infectives |
US7834147B2 (en) * | 2003-04-28 | 2010-11-16 | Childrens Hospital Medical Center | Saposin C-DOPS: a novel anti-tumor agent |
CN102218034A (en) * | 2010-07-29 | 2011-10-19 | 吴赣英 | Formula, preparation method and use of azithromycin liposome combined medicament |
CN104173288A (en) * | 2014-09-03 | 2014-12-03 | 沈阳药科大学 | Clarithromycin ion pair lipidosome injection and preparation method thereof |
WO2015068397A1 (en) | 2013-11-08 | 2015-05-14 | 株式会社アクティバスファーマ | Aqueous suspension preparation comprising nanoparticles of macrolide antibacterial agent |
CN111759811A (en) * | 2020-08-06 | 2020-10-13 | 淄博职业学院 | Non-irritant clarithromycin freeze-dried powder and preparation method thereof |
EP3782627A4 (en) * | 2018-04-17 | 2021-07-07 | Shanghai Tonglian Pharmaceutical Co., Ltd. | Drug used for preventing and/or treating pain and/or fever, combination product, and use thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10695424B2 (en) * | 2016-12-07 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Method of making a liposome composition |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3105793A (en) * | 1956-11-28 | 1963-10-01 | Lobel Mervyn Joseph | Injectable medicinal composition |
WO1987001933A1 (en) * | 1985-09-27 | 1987-04-09 | Liposome Technology, Inc. | Stabilized liposome/amphotericin composition and method |
WO1988006440A2 (en) * | 1987-03-03 | 1988-09-07 | Board Of Regents, The University Of Texas System | Liposome-incorporated nystatin |
WO1989003208A1 (en) * | 1987-10-16 | 1989-04-20 | Board Of Regents, The University Of Texas System | Polyene macrolide pre-liposomal powders |
WO1990004961A1 (en) * | 1988-11-10 | 1990-05-17 | Board Of Regents, The University Of Texas System | Liposomes incorporating aromatic polyene antibiotics |
JPH06239734A (en) * | 1993-02-18 | 1994-08-30 | Kanebo Ltd | Preparation of liposome and loposome formulation |
-
1998
- 1998-01-26 AU AU60414/98A patent/AU6041498A/en not_active Abandoned
- 1998-01-26 WO PCT/US1998/001430 patent/WO1998033482A1/en not_active Application Discontinuation
- 1998-01-26 CA CA002279259A patent/CA2279259A1/en not_active Abandoned
- 1998-01-26 JP JP53298498A patent/JP2001511780A/en active Pending
- 1998-01-26 EP EP98903718A patent/EP0975330A1/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3105793A (en) * | 1956-11-28 | 1963-10-01 | Lobel Mervyn Joseph | Injectable medicinal composition |
WO1987001933A1 (en) * | 1985-09-27 | 1987-04-09 | Liposome Technology, Inc. | Stabilized liposome/amphotericin composition and method |
WO1988006440A2 (en) * | 1987-03-03 | 1988-09-07 | Board Of Regents, The University Of Texas System | Liposome-incorporated nystatin |
WO1989003208A1 (en) * | 1987-10-16 | 1989-04-20 | Board Of Regents, The University Of Texas System | Polyene macrolide pre-liposomal powders |
WO1990004961A1 (en) * | 1988-11-10 | 1990-05-17 | Board Of Regents, The University Of Texas System | Liposomes incorporating aromatic polyene antibiotics |
JPH06239734A (en) * | 1993-02-18 | 1994-08-30 | Kanebo Ltd | Preparation of liposome and loposome formulation |
Non-Patent Citations (5)
Title |
---|
CYPRIAN O. ONYEJI ET AL.: "Efficacies of liposome-encapsulated clarithromycin and ofloxacin against ...", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 38, no. 3, March 1994 (1994-03-01), pages 523 - 527, XP002065380 * |
DATABASE WPI Week 9439, Derwent World Patents Index; AN 94-313609, XP002065383 * |
L. STUHNE-SEKALEC ET AL.: "Liposomes as carrires of macrolides: preferential association of erythromycin A and azithromycin with liposomes...", JOURNAL OF MICROENCAPSULATION, vol. 8, no. 2, April 1991 (1991-04-01), LONDON, GB, pages 171 - 183, XP000216616 * |
SHYAMALA C. JAYARAMAN ET AL.: "Topical delivery of erythromycin from various formulations...", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 85, no. 10, October 1996 (1996-10-01), pages 1082 - 1084, XP002065381 * |
YU-KYOUNG OH ET AL.: "Formulation and efficacy of liposome-encapsulated antibiotics...", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 39, no. 9, September 1995 (1995-09-01), pages 2104 - 2111, XP002065382 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605613B2 (en) | 1998-12-07 | 2003-08-12 | Novartis Ag | Macrolides |
US6852729B2 (en) | 1998-12-07 | 2005-02-08 | Novartis Ag | Macrolides |
US7297703B2 (en) | 1998-12-07 | 2007-11-20 | Novartis Ag | Macrolides |
US7572804B2 (en) | 1998-12-07 | 2009-08-11 | Novartis Ag | Macrolides |
US7741338B2 (en) | 1998-12-07 | 2010-06-22 | Novartis Ag | Macrolides |
JP2003523938A (en) * | 1999-04-16 | 2003-08-12 | コーサン バイオサイエンシーズ, インコーポレイテッド | Macrolide anti-infectives |
WO2000078772A3 (en) * | 1999-06-19 | 2002-03-21 | Univ Manchester | Antibiotic agents |
US6930092B1 (en) | 1999-06-19 | 2005-08-16 | The Victoria University Of Manchester | Antibiotic agents |
WO2000078772A2 (en) * | 1999-06-19 | 2000-12-28 | The Victoria University Of Manchester | Antibiotic agents |
US8937156B2 (en) * | 2003-04-28 | 2015-01-20 | Children's Hospital Medical Center | Saposin C-DOPS: a novel anti-tumor agent |
US7834147B2 (en) * | 2003-04-28 | 2010-11-16 | Childrens Hospital Medical Center | Saposin C-DOPS: a novel anti-tumor agent |
US10188698B2 (en) | 2003-04-28 | 2019-01-29 | Children's Hospital Medical Center | Saposin C-DOPS: a novel anti-tumor agent |
CN102218034A (en) * | 2010-07-29 | 2011-10-19 | 吴赣英 | Formula, preparation method and use of azithromycin liposome combined medicament |
WO2015068397A1 (en) | 2013-11-08 | 2015-05-14 | 株式会社アクティバスファーマ | Aqueous suspension preparation comprising nanoparticles of macrolide antibacterial agent |
CN105658203A (en) * | 2013-11-08 | 2016-06-08 | 株式会社活效制药 | Aqueous suspension preparation comprising nanoparticles of macrolide antibacterial agent |
KR20160079781A (en) | 2013-11-08 | 2016-07-06 | 액티버스 파마 컴퍼니 리미티드 | Aqueous suspension preparation comprising nanoparticles of macrolide antibacterial agent |
RU2707748C2 (en) * | 2013-11-08 | 2019-11-29 | Активус Фарма Ко., Лтд. | Composition of an aqueous suspension comprising nanoparticles of macrolide antibiotics |
US10792248B2 (en) | 2013-11-08 | 2020-10-06 | Activus Pharma Co., Ltd. | Aqueous suspension preparation comprising nanoparticles of macrolide antibacterial agent |
KR20210054068A (en) | 2013-11-08 | 2021-05-12 | 액티버스 파마 컴퍼니 리미티드 | Aqueous suspension formulation comprising nanoparticles of macrolide antibiotics |
CN104173288A (en) * | 2014-09-03 | 2014-12-03 | 沈阳药科大学 | Clarithromycin ion pair lipidosome injection and preparation method thereof |
EP3782627A4 (en) * | 2018-04-17 | 2021-07-07 | Shanghai Tonglian Pharmaceutical Co., Ltd. | Drug used for preventing and/or treating pain and/or fever, combination product, and use thereof |
CN111759811A (en) * | 2020-08-06 | 2020-10-13 | 淄博职业学院 | Non-irritant clarithromycin freeze-dried powder and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2279259A1 (en) | 1998-08-06 |
EP0975330A1 (en) | 2000-02-02 |
JP2001511780A (en) | 2001-08-14 |
AU6041498A (en) | 1998-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6770290B1 (en) | Amphotericin B liposome preparation | |
Lawrence | Surfactant systems: their use in drug delivery | |
JP3626184B2 (en) | Solid fat nanoemulsion as a drug delivery vehicle | |
CA2442539C (en) | Method and composition for solubilising a biologically active compound with low water solubility | |
EP0380584B1 (en) | Polyene macrolide pre-liposomal powders | |
EP0225130A2 (en) | Liposome composition | |
CN107427482A (en) | The multivesicular liposome preparation of tranexamic acid | |
WO1987001933A1 (en) | Stabilized liposome/amphotericin composition and method | |
JP2002507966A (en) | Preparation of pharmaceutical composition | |
EP3138558B1 (en) | Liposome composition and production method therefor | |
PL190628B1 (en) | Pharmaceutic preparation containing lyophilised liposomes surrounding active substance being highly insoluble in water and method of obtaining such preparation | |
WO1998033482A1 (en) | Pain reducing parenteral liposome formulation | |
EP1759699B1 (en) | Liposome preparation containing slightly water-soluble camptothecin | |
WO2005072776A2 (en) | Liposomal formulations of the antineoplastic agents | |
JP4804702B2 (en) | Amphotericin B structured emulsion | |
MXPA99007204A (en) | Pain reducing parenteral liposome formulation | |
US20040175417A1 (en) | Amphotericin B liposome preparation | |
CN112773776B (en) | Drug-loaded nanoparticle system | |
JPH10316555A (en) | Polymer compound-containing liposome external preparation | |
AU2001280084A1 (en) | Amphotericin B structured emulsion | |
JP4694776B2 (en) | Fine particle composition or liposome preparation | |
PL197939B1 (en) | Anti-cancer liposome preparation, method for its manufacture and compound pharmaceutical containing such preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2279259 Country of ref document: CA Ref country code: CA Ref document number: 2279259 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 532984 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/007204 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998903718 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 60414/98 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998903718 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998903718 Country of ref document: EP |